Literature DB >> 12620496

Epithelial neutrophil-activating peptide 78 concentrations are elevated in the peritoneal fluid of women with endometriosis.

Michael D Mueller1, Luca Mazzucchelli, Caroline Buri, Dan I Lebovic, Ekkehard Dreher, Robert N Taylor.   

Abstract

OBJECTIVE: To investigate the presence of epithelial neutrophil-activating peptide 78 (ENA-78) in peritoneal fluid of women with and without endometriosis and to identify the cells that produce this inflammatory protein.
DESIGN: Case-control study.
SETTING: University hospital. PATIENT(S): Eighteen women with and 9 women without endometriosis. MAIN OUTCOME MEASURE(S): ENA-78 protein and mRNA levels were compared among women with and without endometriosis in samples of peritoneal fluid, samples of endometriotic lesions obtained by biopsy during laparoscopy, and peritoneal macrophages. Enzyme-linked immunosorbent assay, reverse transcription polymerase chain reaction, and in situ hybridization methods were used. Secretion of ENA-78 protein by interleukin-1beta-stimulated endometriotic stromal cells and in the media of lipopolysaccharide-stimulated peritoneal macrophages were compared to that in unstimulated cell cultures. RESULT(S): Peritoneal fluid concentrations of ENA-78 were significantly higher in affected women than in controls. Ectopic epithelial and stromal cells and peritoneal macrophages express ENA-78 messenger RNA. Interleukin-1beta stimulation of stromal cell cultures resulted in a 23-fold increase in ENA-78 concentration, and lipopolysaccharide stimulation of peritoneal macrophages increased concentrations by 8-fold. CONCLUSION(S): Levels of ENA-78 are elevated in the peritoneal fluid of women with endometriosis. Ectopic glandular cells, ectopic stromal cells, and peritoneal macrophages express this inflammatory chemokine. Epithelial neutrophil-activating peptide 78 may play an important role in the pathogenesis of endometriosis.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12620496     DOI: 10.1016/s0015-0282(02)04828-8

Source DB:  PubMed          Journal:  Fertil Steril        ISSN: 0015-0282            Impact factor:   7.329


  8 in total

Review 1.  Pathogenesis of Endometriosis: Roles of Retinoids and Inflammatory Pathways.

Authors:  Robert N Taylor; Maureen A Kane; Neil Sidell
Journal:  Semin Reprod Med       Date:  2015-07-01       Impact factor: 1.303

2.  Immune interactions in endometriosis.

Authors:  Jennifer L Herington; Kaylon L Bruner-Tran; John A Lucas; Kevin G Osteen
Journal:  Expert Rev Clin Immunol       Date:  2011-09       Impact factor: 4.473

Review 3.  Endometriosis: hormone regulation and clinical consequences of chemotaxis and apoptosis.

Authors:  Fernando M Reis; Felice Petraglia; Robert N Taylor
Journal:  Hum Reprod Update       Date:  2013-03-28       Impact factor: 15.610

Review 4.  Umbilical endometriosis.

Authors:  F Frischknecht; L Raio; A Fleischmann; E Dreher; K P Lüscher; M D Mueller
Journal:  Surg Endosc       Date:  2004-02       Impact factor: 4.584

5.  PPAR-gamma receptor ligand induces regression of endometrial explants in baboons: a prospective, randomized, placebo- and drug-controlled study.

Authors:  Dan I Lebovic; Jason M Mwenda; Daniel C Chai; Michael D Mueller; Allessandro Santi; Senait Fisseha; Thomas D'Hooghe
Journal:  Fertil Steril       Date:  2007-05-11       Impact factor: 7.329

6.  Enhanced inflammatory activity of endometriotic lesions from the rectovaginal septum.

Authors:  Dominic Bertschi; Brett D McKinnon; Jakob Evers; Nick A Bersinger; Michael D Mueller
Journal:  Mediators Inflamm       Date:  2013-12-28       Impact factor: 4.711

7.  Endometriosis pain and epithelial neutrophil activating peptide-78 levels.

Authors:  Barbara Gardella; Mattia Dominoni; Andrea Gritti; Anna Arrigo; Silvia Antonucci; Giulia Vittoria Carletti; Valentina Musacchi; Giampiero Pietrocola
Journal:  Sci Rep       Date:  2022-02-25       Impact factor: 4.996

8.  Interleukin-1/-33 Signaling Pathways as Therapeutic Targets for Endometriosis.

Authors:  Toru Kato; Koubun Yasuda; Kazufumi Matsushita; Ken J Ishii; Seiichi Hirota; Tomohiro Yoshimoto; Hiroaki Shibahara
Journal:  Front Immunol       Date:  2019-08-22       Impact factor: 7.561

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.